ArticleJournal of veterinary internal medicine2026
Treatment and monitoring of naturally occurring Cushing's syndrome by primary care veterinarians in selected European countries.
Article in Journal of veterinary internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundTreatment of naturally occurring Cushing's syndrome includes surgery or medical management but there is little information on how primary care veterinarians (PCVs) select and monitor such treatment. HYPOTHESIS/
objectivesDetermine how PCVs from selected European countries treat and monitor Cushing's syndrome in dogs.
methodsCross-sectional survey study assessing treatment and monitoring protocols used by PCVs when managing dogs with Cushing's syndrome.
resultsA total of 2178 responses from 9 European countries were included. Overall, 1694 (77.8%) respondents attempted to differentiate functional adrenal tumor (FAT) from pituitary-dependent hypercortisolism (PDH). Adrenalectomy and hypophysectomy were recommended in 67.8% and 30.5% dogs with FAT and PDH, respectively. When surgery was not considered, 23.9% of respondents did not always suggest medical management. Of those recommending medical treatment, 1895/2163 (87.6%) respondents used trilostane either once (60.7%) or twice (39.3%) daily. Time to first follow-up was < 10, 10-14, and 15-30 days for 6.1%, 59.8%, and 31.1% of respondents, respectively. Long-term follow-up was every 3-4 (41.7%) or 5-6 months (37.9%). Monitoring is performed using ACTH stimulation test (54.6%), pre-pill plasma cortisol concentration (18.4%), and both pre- and post-pill plasma cortisol concentration (13.3%). CONCLUSIONS AND CLINICAL IMPORTANCE: Approximately one-third of PCVs do not recommend adrenalectomy for FAT and two-thirds do not recommend hypophysectomy in PDH. Despite demonstrated benefits of medical treatment, one-quarter of respondents do not always recommend it, which may adversely affect life expectancy and quality of life. Treatment and monitoring protocols vary among PCVs. These results suggest that further education of PCVs about management of Cushing's syndrome in dogs may be warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.